Media coverage about Redhill Biopharma (NASDAQ:RDHL) has trended somewhat positive this week, according to Accern Sentiment. Accern identifies positive and negative news coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Redhill Biopharma earned a coverage optimism score of 0.13 on Accern’s scale. Accern also assigned media headlines about the biotechnology company an impact score of 46.4468436098974 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
These are some of the news stories that may have effected Accern’s scoring:
- Redhill Biopharma Ltd. (RDHL) Given Consensus Recommendation of “Buy” by Brokerages (americanbankingnews.com)
- RedHill Biopharma to Present at the BIO-Europe 2017 Conference (finance.yahoo.com)
- Redhill Biopharma (RDHL) versus The Competition Critical Analysis (americanbankingnews.com)
- Amedica Corporation (AMDA) registers a price change of 26.32 … – Stocks Gallery (stocksgallery.com)
- RedHill Biopharma to Present at the BIO-Europe 2017 Conference – GlobeNewswire (press release) (globenewswire.com)
Redhill Biopharma (NASDAQ RDHL) traded down 0.56% during trading on Tuesday, reaching $8.92. The company had a trading volume of 52,477 shares. The company has a 50 day moving average price of $9.17 and a 200 day moving average price of $9.21. The company’s market capitalization is $153.09 million. Redhill Biopharma has a 52-week low of $8.16 and a 52-week high of $12.65.
A number of equities analysts have recently weighed in on RDHL shares. UBS AG started coverage on Redhill Biopharma in a report on Wednesday, September 13th. They issued a “reduce” rating on the stock. Zacks Investment Research upgraded Redhill Biopharma from a “sell” rating to a “hold” rating in a report on Tuesday, August 29th. Roth Capital set a $27.00 target price on Redhill Biopharma and gave the company a “buy” rating in a report on Monday, July 31st. Seaport Global Securities started coverage on Redhill Biopharma in a report on Friday, October 6th. They issued a “buy” rating and a $19.00 target price on the stock. Finally, HC Wainwright set a $33.00 target price on Redhill Biopharma and gave the company a “buy” rating in a report on Wednesday, July 26th. One analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the stock. Redhill Biopharma has an average rating of “Buy” and an average target price of $23.35.
COPYRIGHT VIOLATION WARNING: This article was posted by Community Financial News and is the property of of Community Financial News. If you are reading this article on another domain, it was stolen and republished in violation of U.S. & international copyright and trademark laws. The original version of this article can be accessed at https://www.com-unik.info/2017/10/31/redhill-biopharma-rdhl-receives-daily-media-sentiment-score-of-0-13.html.
Redhill Biopharma Company Profile
Redhill Biopharma Ltd, is an Israel-based specialty biopharmaceutical company. The Company focuses on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases and cancer. It offers the following gastrointestinal products in the United States: Donnatal, a prescription oral adjunctive drug used in the treatment of Irritable Bowel Syndrome (IBS) and acute enterocolitis, as well as EnteraGam, a medical food intended for the dietary management, under medical supervision, of chronic diarrhea and loose stools.
What are top analysts saying about Redhill Biopharma Ltd.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Redhill Biopharma Ltd. and related companies.